

Table 1: mRNA-1273 Drug Product Modeling Purity Stability Data, -60°C to -90°C

Lot	Purpose	Purity Method	Time Point (months)									
AMPDP-200005	Development	(b) (4)										
DH-02838	Development											
DH-03453.3	Development											
DH-03453.3	Development											
DHM-47516	Development											
DHM-47516	Development											
DHM-47517	Development											
DHM-47517	Development											
DHM-47519	Development											
DHM-47519	Development											
DHM-47521	Development											
DHM-47521	Development											
DHM-49621	Development											
DHM-53331	Development											
DHM-53331	Development											
6007520001	Clinical											
6007520002	Clinical											
6007520003	Clinical											
6007520004	Clinical											
6007520005	Clinical											
6007520006	Clinical											

(b) (4)

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Table 2: mRNA-1273 Drug Product Modeling Purity Stability Data, -40°C ± 5°C

Lot	Purpose	Purity Method	Time Point (months)						
			0	1	2	3	6	9	12
DH-03453.1	Development	(b) (4)							
DH-03453.1	Development								
DH-03453.2	Development								
DH-03453.2	Development								
DHM-47504	Development								
DHM-47504	Development								
DHM-47519	Development								
DHM-47519	Development								

(b) (4)

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Table 3: mRNA-1273 Drug Product Modeling Purity Stability Data, -20°C ± 5°C

Lot	Purpose	Purity Method	Time Point (months)									
			0	1	2	3	4	4.6	5	6	9	12
DH-03453.1	Development	(b) (4)										
DH-03453.1	Development											
DH-03453.1 (PC)	Development											
DH-03453.1 (PC)	Development											
DH-03453.2	Development											
DH-03453.2	Development											
DH-03453.2 (PC)	Development											
DH-03453.2 (PC)	Development											
DHM-47504	Development											
DHM-47504	Development											
DHM-47517	Development											
DHM-47517	Development											
DHM-47519	Development											
DHM-47519	Development											
DHM-47521	Development											
DHM-47521	Development											
6007320001	Scale A											
6007320002	Scale A											
6007320003	Scale A											
6007520001	Clinical											
6007520002	Clinical											
6007520003	Clinical											
6007520004	Clinical											

(b) (4)

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.

Table 4: mRNA-1273 Drug Product Modeling Purity Stability Data, 5°C ± 3°C

Lot	Purpose	Purity Method	Time Point (months)													
			0	0.1	0.23	0.46	0.69	0.92	1	2	2.3	2.5	3	4	4.14	5
AMPDP-200005	Development	(b) (4)														
DH-02838	Development															
DH-03453.1	Development															
DH-03453.1 PC	Development															
DH-03453.1 PC Inverted	Development															
DH-03453.2	Development															
DH-03453.2 PC	Development															
DH-03453.2 PC Inverted	Development															
DH-03453.3	Development															
DH-03453.3	Development															
DHM-47504	Development															
DHM-47517	Development															
DHM-47519	Development															
DHM-47521	Development															
DHM-49621	Development															
DHM-53331	Development															
DHM-53331	Development															
6007520001	Clinical															
6007520002	Clinical															
6007520003	Clinical															

(b) (4)

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.



Table 5: mRNA-1273 Drug Product Modeling Purity Stability Data, 25°C ± 2°C

Lot	Purpose	Time Point (h)		
		0	24	72
6007320001	Scale A	(b) (4)		
6007320002	Scale A			
6007320002	Scale A			
6007520001	Clinical			
6007520002	Clinical			
6007520003	Clinical			
6007520004	Clinical			

Abbreviation: N/A = not applicable

CONFIDENTIAL – DO NOT DISTRIBUTE OUTSIDE OF MODERNATX, INC. WITHOUT WRITTEN PERMISSION.